Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 19, 2023 1:39pm
109 Views
Post# 35548347

RE:RE:Wino is MIA?

RE:RE:Wino is MIA?Same for me, I did not comment because there is nothing interesting to comment about. The story is repeating itself with Thera, and Levesque looks more and more like a new John Huss. He is now doing the same thing Huss did back around 2011, laying off R&D employees to cover his failures as CEO. So speciality pharmacies were expecting a higher demand with Egrifta and Trogarzo, but thanks to our great marketing department, Thera was unable to deliver on those expectations. With Thera always expect mild failures, that's why they still exist as a company. They never achieve real commercial success and more often than not miis on their own guidance. It's the same story with this company, the R&D side delivers, but the rest is not as good, and the first to pay are the R&D people, always. Their failure to come up with a good protocol for phase I of TH1902 cost the jobs of many scientists there. Levesque said he was in discussions with companies interested to develop new PDC with TH19P01 and their own cytotoxic agents. Who will do this work now that he closed the R&D lab? What about new PDCs with SN38, other cytotoxic agents or siRNA? All that is on hold at best. So nothing positive to talk about. My level of trust in this management is very low now. Levesque looks like a bad BS artist than anything else. He is unable to deliver on anything. It's all promises, no accomplishments. Their credibility problem is deeper than ever.
<< Previous
Bullboard Posts
Next >>